Articles tagged with Prostate Cancer
A prospective study found that smoking significantly increases a woman's risk for peripheral artery disease (PAD), which can cause pain and discomfort. The study also suggests that smoking cessation reduces the risk, but even after 20 years of abstention, the risk remains elevated.
A new targeted therapy, G-1, has been shown to halt the growth of tumors in animals with advanced prostate cancer resistant to hormone therapy. The treatment works by targeting and activating protein GPR30, which sensitizes tumor cells to its inhibiting effects.
Men with prostate cancer treated with hormone deprivation therapy may be at increased risk of developing diabetes or metabolic syndrome. According to the study, men in the ADT group had a twofold increased probability of having diabetes compared to those who did not receive hormonal therapy.
A multicenter clinical trial found stereotactic body radiation therapy (SBRT) to be an effective treatment option for patients with localized prostate cancer, delivering results in just five 30-minute sessions. The study's findings suggest that higher doses of radiation are safe and can lead to improved outcomes.
Researchers found that itraconazole can delay the progression of prostate cancer and reduce PSA levels, with 48.4% of patients experiencing stable or declining PSA after high-dose treatment. The antifungal also disrupted a key cancer-initiating biological pathway called Hedgehog.
A new experimental vaccine made from frozen immune cells has shown promise in extending the survival of metastatic prostate cancer patients. The vaccine, APC8015F, was found to increase median survival by approximately 10 months compared to those not treated with it.
A new study shows that abiraterone acetate, a life-extending pill for advanced prostate cancer, prolongs survival by about four months compared to placebo. The medication also reduces PSA blood levels in patients with the disease.
A recent study found that men who walk briskly after diagnosis have a 57% lower rate of progression of disease than those who walk at an easy pace. Brisk walking can delay or even prevent progression of prostate cancer.
A study of 1,455 U.S. men with early-stage prostate cancer found that brisk walking lowers the risk of prostate cancer progression by nearly 60%. Regular physical activity can improve prognosis, and walking must be brisk for benefits to occur.
A new study by American Cancer Society researchers found that long-term regular acetaminophen use was associated with a 38% lower risk of prostate cancer. The study suggests that acetaminophen may provide biological clues about prostate cancer development, warranting further research.
A genome-wide association study found a novel risk variant on chromosome 17q21 that is common in African American men but rare in other populations. This discovery builds on previous research identifying a risk region on chromosome 8q24, suggesting a genetic contribution to racial disparities in prostate cancer risk.
New studies released by ASCO highlight advances in cervical cancer screening, ovarian cancer detection, and prostate cancer risk prediction. The studies also explore genetic biomarkers for chemotherapy-induced neuropathy and potential treatments for relapsed ovarian cancer.
A new study from the University of Michigan Comprehensive Cancer Center finds that half of prostate cancers have a genetic anomaly making them responsive to PARP inhibitors. These drugs are being tested in breast cancer patients and show promise in shrinking tumors and blocking cancer spread.
A new study shows that nearly 70% of men with rising PSA levels and subsequent normal biopsies were eventually diagnosed with prostate cancer. Rising PSA velocity over several years should prompt clinicians to follow patients more closely, even with negative biopsy results.
A large-scale study found that men who drink coffee regularly have a lower risk of developing lethal prostate cancer. The study, led by Harvard School of Public Health researchers, also showed that decaf and regular coffee both reduced the risk, with even moderate consumption offering significant protection.
A new test measuring multiple parameters including PSA and six antibodies found in the blood of men with prostate cancer is more sensitive and specific than the conventional PSA test. The A+PSA assay reduces false-positives and shows great potential to improve prostate cancer diagnosis.
Men who are overweight or obese face a three-fold increased risk of cancer progression and more than a three-fold increased risk of metastases compared to normal-weight men. Obesity is linked to poorer outcomes in prostate cancer patients, regardless of treatment.
Researchers at Mayo Clinic found that patients diagnosed with advanced prostate cancer can enjoy long-term survival and a significant cancer-free interval. The study showed an 80% survival rate for patients with locally advanced prostate cancer at 20 years after surgery.
A new technology fusion of MRI with real-time 3D ultrasound improves targeted biopsy accuracy for prostate cancer diagnosis. The system identifies suspicious areas in the prostate and provides a roadmap for biopsy needle guidance, increasing cancer detection rates by five times compared to conventional biopsies.
Researchers combine Sabutoclax with viral gene therapy to prevent tumor growth in prostate-cancer-prone mice, offering a novel approach to treating advanced prostate cancer. The study's findings suggest that this combination therapy could be effective in other cancers and pave the way for personalized medicine.
Researchers find increased MAN2C1 levels enhance prostate cancer recurrence and metastasis, highlighting a potential target for blocking tumor progression. The study could lead to the development of new treatments for patients with advanced prostate cancer.
Scientists selectively sensitized prostate cancer cells to radiation therapy by knocking down a key protein repair gene. The approach shows promise for treating locally advanced prostate cancer, reducing disease recurrence.
A new biomarker for diagnosing prostate cancer has been found to be more reliable than current methods, reducing false positives and unnecessary operations. The study, published in PNAS, uses a unique test that detects elevated levels of prostasomes in blood, which are released by cancer cells into the surrounding tissue.
A Swedish research team found that surgery significantly reduces prostate cancer mortality risk, even among men with low-risk tumours. The study followed 347 patients and found that surgical patients had a lower risk of dying from prostate cancer than those who underwent watchful waiting.
A recent study published at the American Radium Society Annual Meeting found that aspirin use lowers the risk of cancer recurrence in prostate cancer patients who have received radiotherapy. After 10 years, men taking aspirin had a 31% lower rate of biochemical failure compared to non-aspirin users.
Researchers found that tissue spacers significantly reduced the rectal dose administered to patients receiving radiation therapy for prostate cancer. This led to minimal damage to the rectum, enabling radiation oncologists to increase treatment doses without concern.
Researchers at Georgetown University Medical Center report that a drug developed to treat Ewing's Sarcoma may also prevent human prostate cancer from spreading. The agent, YK-4 279, was found to inhibit functions of proteins responsible for aggressive cell behavior in prostate cancer cells.
Scripps Research and Moffitt Cancer Center collaborate on a $2.1 million grant to understand the origins of prostate cancer and develop novel treatments. The study aims to define how B cells control the spread of hormone-refractory cancer, potentially leading to effective treatments.
A nationwide study found that men with high levels of omega-3 fatty acids in their blood have a two-and-a-half times higher risk of developing aggressive prostate cancer. In contrast, those with high levels of trans-fatty acids had a 50% lower risk of high-grade prostate cancer.
A new study published in The Journal of Urology found that testosterone therapy does not cause rapid growth of prostate cancer in men with untreated or low-risk prostate cancer. Testosterone treatment was associated with improved symptoms and quality of life, without increasing the risk of cancer progression.
Thomas Jefferson University researchers show intensity-modulated radiotherapy (IMRT) delivers higher doses to the prostate bed while sparing surrounding tissue, leading to improved PSA levels and reduced side effects. The study fills a gap in documentation of this technique's benefits for post-operative patients.
A large-scale study of 769 men with low-grade prostate cancer found that closely monitoring the disease without immediate treatment does not raise the risk of death. Men who undergo active surveillance are less likely to need subsequent surgery or radiation if their cancer progression is carefully monitored.
A new PSA test has been shown to detect aggressive prostate cancer more accurately than current tests and reduce unnecessary biopsies. The Pro-PSA test uses a specific PSA subform called (-2) Pro-PSA and can be analyzed with a mathematical formula to provide an overall Prostate Health Index.
Researchers at Fox Chase Cancer Center have discovered two novel genetic markers associated with earlier time to prostate cancer diagnosis among African American men. Genetic variations in miRNA binding sites, particularly in genes IL-16 and IL-18, were found to increase the risk of early diagnosis.
U-M scientists identified a genetic anomaly in the KRAS gene, known for its role in numerous cancers, that may promote tumor progression in a rare subset of prostate cancers. This finding suggests different subtypes of prostate cancer will need targeted treatment strategies.
Researchers have identified an oncogenic gene fusion of KRAS in a metastatic prostate cancer cell line, shedding light on the genetic characteristics of this disease. This finding may enable better prognostic information to separate slow-growing tumors from aggressive ones, ultimately improving treatment strategies.
Researchers found that men using digoxin had a 24% lower risk of prostate cancer. The study also identified other approved drugs with anti-prostate cancer properties, paving the way for further research and potential new treatments.
A multidisciplinary team identified digoxin as a possible therapy for prostate cancer through drug repositioning. Regular digoxin use reduced the risk of prostate cancer by 24% and 46% for long-term users, respectively.
Researchers have found a new method for detecting prostate cancer that analyzes non-tumor tissue, potentially improving diagnosis accuracy. This approach could help reduce the number of repeat biopsies and improve patient outcomes.
A new study found that nearly half of elderly men in their seventies underwent PSA screening, while those aged 85 and older screened just as often as those in their early fifties. The high rate of unnecessary screenings may lead to complications such as incontinence and impotence.
A new study found that combining 6 months of hormone therapy with radiotherapy significantly improved survival rates for men with locally advanced prostate cancer. The treatment reduced the risk of death from prostate cancer by half and deaths from any cause by a third compared to radiation alone.
A study of over 3,000 patients found robot-assisted prostate surgery to be safe, with a low major complication rate and no disease recurrence after five years for nearly 87 percent of patients. The study analyzed surgical outcomes from 2005 to 2009 and addressed the lack of standardized reporting in previous literature.
Research from Brigham and Women's Hospital shows rapid adoption of newer, more expensive prostate cancer treatments between 2002-2005 without proof of cost-effectiveness. This trend is reflected in increased Medicare spending on these treatment options, which rose nearly $350 million in 2005.
A new study published in Medical Care found that hospitals with robotic technology are more likely to perform radical prostatectomy surgeries. This is the first study to investigate the impact of surgical robot acquisition on surgery rates, and it concludes that technological adoption leads to increased surgical volume.
A UCLA research team has developed a device using Velcro-like nanoscale technology to efficiently identify and capture circulating tumor cells, or CTCs, in blood samples. The new approach captures a greater number of CTCs than existing methods and could enable early detection and diagnosis of cancer.
Scientists have identified a potential target to treat an aggressive type of prostate cancer, known as SPINK1. A 'blocking' antibody to SPINK1 reduced tumor growth by up to 74% in mice. The study suggests that targeting SPINK1 may be effective in treating SPINK1-positive tumors.
A phase 3 study shows that denosumab delays and prevents bone events in men with castration-resistant prostate cancer, improving outcomes compared to zoledronic acid. Denosumab reduces the risk of bone fractures and other complications by inhibiting osteoclast activity.
Research suggests that PSA velocity is a poor predictor of prostate cancer and can lead to unnecessary biopsies. The study found that men with rapid rises in PSA levels did not have cancer more often than those with slower rises, highlighting the need for alternative screening methods.
Researchers found that PSA velocity is a poor predictor of prostate cancer and may lead to unnecessary biopsies. The study, which analyzed data from over 5,000 men, suggests that using changes in PSA levels as a basis for recommending biopsy can result in many unnecessary procedures.
New studies reveal a low initial PSA score of 3.0 ng/ml is an appropriate minimum cut-off level for biopsy targeting those at risk, while proficiency in robotic-assisted prostate surgery requires over 1,600 surgeries to master. Dutasteride may also slow early-stage prostate cancer growth.
A French study found that men who start losing hair at age 20 are twice as likely to develop prostate cancer compared to healthy men. The study also suggested that balding may be a potential risk factor for prostate cancer.
Whole genome sequencing reveals new genes tied to prostate cancer growth, including those disrupting tumor suppressors and heat shock proteins. The study identifies genomic rearrangements that may be driving cancer development and suggests a link between gene activity and DNA rearrangement.
The study reveals several new prostate cancer genes, including those disrupting tumor suppressor proteins and rearrangements that create new genes. These findings may provide insights into the disease's development and suggest potential diagnostic markers and new treatments for aggressive forms of prostate cancer.
Researchers found that dutasteride is impractical due to high costs and marginal impact on survival and quality of life for at-risk groups. The medication's annual cost of $1,400 outweighs its benefits, making it less effective as a preventive measure.
A four-gene signature has been identified as a reliable predictor of metastatic prostate cancer, outperforming traditional methods in accuracy. The discovery could lead to the development of gene-based tests for determining prostate cancer's potential to spread.
Researchers found a protein called FUS that inhibits prostate cancer cell growth and activates pathways leading to cell suicide. Higher levels of FUS correlate with less aggressive cancer and longer survival.
A research project aims to analyze the genomes of 250 prostate cancer patients under 50 to identify genetic mutations that cause and promote the disease. The goal is to produce a comprehensive map of genetic modifications involved in prostate cancer, which may lead to new treatment approaches and diagnostic methods.
Researchers at UT MD Anderson Cancer Center found that a specific microRNA, miR-34a, suppresses prostate cancer stem cells and metastasis by targeting the surface protein CD44. The study provides a strong rationale for developing new treatment options for prostate cancer.
Researchers discovered that SIRT1 inhibits prostatic intraepithelial neoplasia (PIN), a precursor to prostate cancer, by promoting autophagy. The study suggests that activating SIRT1 could block prostate cancer and promote longevity.
A recent study published in the Journal of Biological Chemistry reveals that PSA (prostate-specific antigen) levels correlate with prostate cancer progression due to a complex formed between PSA and cell surface receptor GRP78. This binding stimulates pathways promoting tumor growth, cell movement, and blocking apoptosis.